Table 1.

Overall response rates (ORR) and histologic subtypes in Phase II trials of anti-PD-1/PD-L1 therapy in ovarian cancer.

Trial	Monotherapy	ORR	Literature
UMIN00000571	Nivolumab	1/2 clear cell (50%) 2/18 others (11%)	Hamanishi et al., 2015 [48]
NCT01375842	Atezolizumab	1/1 clear cell (100%) 1/9 others (11%)	Liu et al., 2019 [49]
NCT02674061 (KEYNOTE-100)	Pembrolizumab	3/19 clear cell (16%) 24/332 others (7.2%)	Matulonis et al., 2019 [50] Matulonis et al., 2020 [51]
NCT01772004 (JAVELIN Solid Tumour)	Avelumab	2/2 clear cell (100%) 10/123 others (8.1%)	Disis et al., 2019 [52]